Medicare expenditures for patients with amyotrophic lateral sclerosis are more than 3 times those of the average Medicare beneficiary, and drug therapies are an important cost driver.
Kuldip D. Dave, PhD
Advertisement
Articles by Kuldip D. Dave, PhD
Advertisement
Latest Updated Articles
Medicare Expenditures in the First Year of Amyotrophic Lateral Sclerosis DiagnosisPublished: October 20th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
3
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
4
Medicare’s 3-Day Rule Reinstatement Lengthened Hospital Stays Without Cost, Outcome Benefits
5